$218.83
35.41[19.31%]
At close: Apr 26
$218.83
0[0.00%]
After Hours: 7:58PM EDT
ResMed Stock (NYSE:RMD), Analyst Ratings, Price Targets, Predictions
ResMed Inc has a consensus price target of $165, established from looking at the 67 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, RBC Capital, and Keybanc on April 26, 2024. With an average price target of $212.67 between Oppenheimer, RBC Capital, and Keybanc, there's an implied -2.82% downside for ResMed Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
RBC Capital
Keybanc
Needham
Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ResMed
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/26/2024 | RMD | Buy Now | ResMed | $218.83 | -8.6% | Oppenheimer | Suraj Kalia | $205 → $200 | Maintains | Outperform | Get Alert |
| 04/26/2024 | RMD | Buy Now | ResMed | $218.83 | -8.6% | RBC Capital | Craig Wong-Pan | $187 → $200 | Maintains | Sector Perform | Get Alert |
| 04/26/2024 | RMD | Buy Now | ResMed | $218.83 | 8.76% | Keybanc | Brett Fishbin | $227 → $238 | Maintains | Overweight | Get Alert |
| 04/26/2024 | RMD | Buy Now | ResMed | $218.83 | 7.85% | Needham | Mike Matson | $224 → $236 | Maintains | Buy | Get Alert |
| 04/01/2024 | RMD | Buy Now | ResMed | $218.83 | 2.36% | Needham | Mike Matson | $215 → $224 | Maintains | Buy | Get Alert |
| 03/27/2024 | RMD | Buy Now | ResMed | $218.83 | -1.75% | Mizuho | Anthony Petrone | $215 → $215 | Maintains | Buy | Get Alert |
| 02/06/2024 | RMD | Buy Now | ResMed | $218.83 | 3.73% | Keybanc | Brett Fishbin | → $227 | Initiates | → Overweight | Get Alert |
| 01/30/2024 | RMD | Buy Now | ResMed | $218.83 | -6.32% | Oppenheimer | Suraj Kalia | $185 → $205 | Maintains | Outperform | Get Alert |
| 01/30/2024 | RMD | Buy Now | ResMed | $218.83 | -1.75% | Mizuho | Anthony Petrone | $195 → $215 | Maintains | Buy | Get Alert |
| 01/26/2024 | RMD | Buy Now | ResMed | $218.83 | -10.89% | Mizuho | Anthony Petrone | $180 → $195 | Maintains | Buy | Get Alert |
| 01/25/2024 | RMD | Buy Now | ResMed | $218.83 | -17.74% | UBS | Saul Hadassin | $175 → $180 | Maintains | Neutral | Get Alert |
| 01/25/2024 | RMD | Buy Now | ResMed | $218.83 | -16.83% | RBC Capital | Craig Wong-Pan | $181 → $182 | Maintains | Sector Perform | Get Alert |
| 01/25/2024 | RMD | Buy Now | ResMed | $218.83 | -1.75% | Needham | Mike Matson | $180 → $215 | Maintains | Buy | Get Alert |
| 01/09/2024 | RMD | Buy Now | ResMed | $218.83 | -10.89% | JP Morgan | David Low | $160 → $195 | Maintains | Overweight | Get Alert |
| 10/31/2023 | RMD | Buy Now | ResMed | $218.83 | -26.88% | Mizuho | Anthony Petrone | $180 → $160 | Maintains | Buy | Get Alert |
| 10/27/2023 | RMD | Buy Now | ResMed | $218.83 | -22.77% | Morgan Stanley | Sean Laaman | → $169 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/16/2023 | RMD | Buy Now | ResMed | $218.83 | -20.03% | Oppenheimer | Suraj Kalia | $275 → $175 | Maintains | Outperform | Get Alert |
| 10/12/2023 | RMD | Buy Now | ResMed | $218.83 | -7.69% | RBC Capital | Craig Wong-Pan | $273 → $202 | Downgrade | Outperform → Sector Perform | Get Alert |
| 09/29/2023 | RMD | Buy Now | ResMed | $218.83 | — | Wolfe Research | Mike Polark | — | Downgrade | Outperform → Peer Perform | Get Alert |
FAQ
What is the target price for ResMed (RMD)?
The latest price target for ResMed (NYSE: RMD) was reported by Oppenheimer on April 26, 2024. The analyst firm set a price target for $200.00 expecting RMD to fall to within 12 months (a possible -8.60% downside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ResMed (RMD)?
The latest analyst rating for ResMed (NYSE: RMD) was provided by Oppenheimer, and ResMed maintained their outperform rating.
When was the last upgrade for ResMed (RMD)?
The last upgrade for ResMed Inc happened on October 27, 2023 when Morgan Stanley raised their price target to $169. Morgan Stanley previously had an equal-weight for ResMed Inc.
When was the last downgrade for ResMed (RMD)?
The last downgrade for ResMed Inc happened on October 12, 2023 when RBC Capital changed their price target from $273 to $202 for ResMed Inc.
When is the next analyst rating going to be posted or updated for ResMed (RMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on April 26, 2024 so you should expect the next rating to be made available sometime around April 26, 2025.
Is the Analyst Rating ResMed (RMD) correct?
While ratings are subjective and will change, the latest ResMed (RMD) rating was a maintained with a price target of $205.00 to $200.00. The current price ResMed (RMD) is trading at is $218.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.